866-997-4948(US-Canada Toll Free)

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Oct 2013

Category :

Oncology

No. of Pages : 97 Pages


Global Markets Directs, \'Waldenstrom Macroglobulinemia Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia. Waldenstrom Macroglobulinemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Waldenstrom Macroglobulinemia.
  • A review of the Waldenstrom Macroglobulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Waldenstrom Macroglobulinemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Waldenstrom Macroglobulinemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Waldenstrom Macroglobulinemia 8
Waldenstrom Macroglobulinemia Therapeutics under Development by Companies 10
Waldenstrom Macroglobulinemia Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Waldenstrom Macroglobulinemia Therapeutics - Products under Development by Companies 17
Waldenstrom Macroglobulinemia Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Waldenstrom Macroglobulinemia Therapeutics Development 19
Gilead Sciences, Inc. 19
Millennium Pharmaceuticals, Inc. 20
Genmab A/S 21
Celgene Corporation 22
Onyx Pharmaceuticals, Inc. 23
Accentia Biopharmaceuticals, Inc. 24
Pharmacyclics, Inc. 25
Immune System Therapeutics Ltd. 26
Waldenstrom Macroglobulinemia - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ibrutinib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
dasiprotimut T - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MDX-1097 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
carfilzomib - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
idelalisib - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MLN-0128 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ofatumumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
scFV-Chemokine DNA Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CC-292 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ABT-199 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KPT-330 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Waldenstrom Macroglobulinemia Therapeutics - Drug Profile Updates 58
Waldenstrom Macroglobulinemia Therapeutics - Discontinued Products 87
Waldenstrom Macroglobulinemia Therapeutics - Dormant Products 88
Waldenstrom Macroglobulinemia - Product Development Milestones 89
Featured News & Press Releases 89
Jun 20, 2013: Pharmacyclics Presents Ibrutinib Monotherapy Clinical Trial Data In Patients With Waldenstrom\'s Macroglobulinemia At ICML 89
Apr 01, 2013: Onyx Pharma To Present Data On Oprozomib At 14th International Myeloma Workshop 90
Feb 12, 2013: Janssen Announces FDA Grants Two Oncology Breakthrough Therapy Designations For Ibrutinib 90
Dec 06, 2012: TG Therapeutics To Present Clinical Data On Ublituximab At 54th American Society Of Hematology Meeting 91
Nov 06, 2012: Onyx Pharma Announces Data Presentations On Oprozomib At 54th American Society Of Hematology Annual Meeting 92
Nov 08, 2011: Genmab To Present Data On Ofatumumab At 53rd American Society Of Hematology Annual Meeting And Exposition 92
Nov 07, 2011: Pharmacyclics Reports Multiple PCI-32765 Presentations At 53rd American Society Of Hematology Annual Meeting 93
Jun 29, 2007: Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on Krx-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom\'s Macroglobulinemia 94

Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 97
Disclaimer 97

List of Table


Number of Products Under Development for Waldenstrom Macroglobulinemia, H2 2013 8
Products under Development for Waldenstrom Macroglobulinemia - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Late Stage Development, H2 2013 13
Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Clinical Stage Development, H2 2013 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 16
Products under Development by Companies, H2 2013 17
Products under Investigation by Universities/Institutes, H2 2013 18
Gilead Sciences, Inc., H2 2013 19
Millennium Pharmaceuticals, Inc., H2 2013 20
Genmab A/S, H2 2013 21
Celgene Corporation, H2 2013 22
Onyx Pharmaceuticals, Inc., H2 2013 23
Accentia Biopharmaceuticals, Inc., H2 2013 24
Pharmacyclics, Inc., H2 2013 25
Immune System Therapeutics Ltd., H2 2013 26
Assessment by Monotherapy Products, H2 2013 27
Assessment by Stage and Route of Administration, H2 2013 29
Assessment by Stage and Molecule Type, H2 2013 31
Waldenstrom Macroglobulinemia Therapeutics - Drug Profile Updates 58
Waldenstrom Macroglobulinemia Therapeutics - Discontinued Products 87
Waldenstrom Macroglobulinemia Therapeutics - Dormant Products 88

List of Chart


Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2013 8
Products under Development for Waldenstrom Macroglobulinemia - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 12
Late Stage Products, H2 2013 13
Mid Clinical Stage Products, H2 2013 14
Early Clinical Stage Products, H2 2013 15
Pre-Clinical Stage Products, H2 2013 16
Assessment by Monotherapy Products, H2 2013 27
Assessment by Route of Administration, H2 2013 28
Assessment by Stage and Route of Administration, H2 2013 29
Assessment by Molecule Type, H2 2013 30
Assessment by Stage and Molecule Type, H2 2013 31

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *